Verastem Inc (VSTM)

1.240
-0.010(-0.80%)
After Hours
1.300
+0.060(+4.839%)
- Real-time Data
  • Volume:
    1,117,532
  • Day's Range:
    1.195 - 1.270
  • 52 wk Range:
    1.000 - 4.930

VSTM Overview

Prev. Close
1.25
Day's Range
1.195-1.27
Revenue
3.65M
Open
1.22
52 wk Range
1-4.93
EPS
-0.41
Volume
1,117,532
Market Cap
231.09M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,362,533
P/E Ratio
-
Beta
0.91
1-Year Change
-67.96%
Shares Outstanding
186,361,206
Next Earnings Date
Aug 10, 2022
What is your sentiment on Verastem?
or
Market is currently closed. Voting is open during market hours.

Verastem Inc News

Verastem Inc Analysis

Verastem Inc Company Profile

Verastem Inc Company Profile

Employees
49

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen’s KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyNeutralStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell
  • Any news?
    0
    • TUSK double the price very soon..Very low volume.. Easy to jump.. Don't miss it.. Good luck guys..
      1
      • They are working on a cancer medicine.. Finish the two stages.. Waiting to finish the third stage to fly like a rocket..
        0
        • 3 soon
          0
          • TUSK double the price very soon..
            0
            • Ride or die
              0
              • Oh cousin :) are we on the same ride
                0
            • Someone picked up 1,962,672 at $2.01 yesterday right before close That's $3,959,040.72
              0
              • Buy and hold..1st target 3usd soon.. 2nd target 4usd
                0
                • Lets go up.. I think it takes long enough.. Now time to jump up..
                  0
                  • lol
                    0